NCT03969446View on ClinicalTrials.gov

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 4, 2020

Primary Completion Date

November 4, 2025

Study Completion Date

November 4, 2025

Conditions

Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaRefractory Myelodysplastic Syndrome

Interventions

DRUG

Decitabine

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Venetoclax

Given PO

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER